Magnetic resonance imaging (MRI) software solutions company SyntheticMR has secured regulatory clearance in the UK for version 15 of its next-generation imaging solution, SyMRI Neuro.
SyntheticMR’s SyMRI suite of technologies generates adjustable contrast images and quantitative data from a five-minute scan. SyMRI 15 builds upon the previous SyMRI 3D (14) and delivers detailed brain imaging, tissue segmentation, and quantitative analysis. The solution includes a host of advanced applications integrated into SyMRI’s post-processing suite.
According to the Swedish software company, SyMRI 15 has been clinically validated in a large multi-centre study across the US. Data showed that SyMRI 3D can replace conventional 3D imaging, enhancing both efficiency and throughput.
SyntheticMR’s CEO Ulrik Harrysson said: “The approval in the UK represents a significant step in SyntheticMR’s global expansion strategy and signifies strong potential for growth and increased market presence in Europe.
“We are thrilled to announce that version 15 of our 3D SyMRI solution is now available in the UK. This next generation of SyMRI 3D delivers unparalleled resolution and accuracy in brain imaging, transforming the field of medical diagnostics.”
SyntheticMR teamed up with Philips in February 2024, announcing the launch of Smart Quant Neuro 3D. The technology provides auto measurement of various brain tissues to enhance decision support of brain disease, assess progression and monitor the effect of therapy in brain disorders such as multiple sclerosis (MS), traumatic brain injury (TBI), and dementia.
The software comes as a combination of three previously released programmes, the SmartSpeed image-reconstruction technology, Philips 3D SyntAc clinical application and SyntheticMR’s SyMRI NEURO 3D quantitative tissue assessment software.
In 2019, SyntheticMR announced US Food and Drug Administration (FDA) clearance for clinical use of its SyMRI Image and SyMRI Neuro product packages together with MRI systems from Siemens Healthineers. Version 15 of SyMRI Neuro also secured a CE mark in June 2024.
SyntheticMR are not the only players in the MRI space. Earlier this week, Hyperfine presented positive interim data from the ACTION PMR study, demonstrating that its MRI Swoop system offers faster time-to-scan compared to conventional MRI, along with good specificity in emergency stroke care.
According to GlobalData insights, Hyperfine is one of the key players in AI-assisted MRI, which is set to be a disruptive innovation in the medical devices industry.
